Neurological Adverse Reactions to Anticancer Drugs
In this timely and up-to-date book, the latest knowledge on neurological syndromes due to neurotoxicity of antineoplastic drugs is presented. The initial chapters discuss the following vital topics: - the importance of blood-brain barrier changes in cance
- PDF / 15,285,034 Bytes
- 100 Pages / 595 x 785 pts Page_size
- 48 Downloads / 234 Views
J. Hildebrand (Ed.)
Neu rolog ical Adverse Reactions to Anticancer Drugs With 8 Figures and 15 Tables
Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona
Jerzy Hildebrand Service de Neurologie H6pital Erasme Universite Libre de Bruxelles Route de Lennik, 808 1070 Bruxelles, Belgium
"The European School of Oncology gratefully acknowledges sponsorship for the Task Force received by Fidia S.pA, the discoverers and marketers of CRONASSIAL® (gangliosides), a drug experimentally proven to be effective in enhancing the intrinsic repair mechanisms of neural tissue in vincristine neuropathy".
ISBN-13: 978-3-642-76144-7 e-ISBN-13: 978-3-642-76142-3 DO I: 10.1007/ 978-3-642-76142-3
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its current version, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.
© Springer-Verlag Berlin Heidelberg 1990 Soflcover reprint of the hardcover 15t edition 1990
The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.
2123/3145-543210 - Printed on acid-free paper
Foreword
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between t
Data Loading...
